anti-CD19-CAR T-cells-Affiliated Hospital of Nantong University-B-cell acute lymphoblastic leukemia-non-Hodgkin lymphoma-Hodgkin lymphoma-T-cell lymphoma

anti-CD19-CAR T-cells (Affiliated Hospital of Nantong University) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen. Developed by the Affiliated Hospital of Nantong University, this cell therapy involves the genetic modification of a patient's own T-cells to express a CAR construct designed to recognize and bind to CD19, a protein predominantly expressed on the surface of B-cells and B-cell derived malignancies. Upon binding to CD19-positive cells, the CAR T-cells are activated to induce targeted cell lysis. The therapy is currently being evaluated in an early Phase 1 clinical trial (NCT04011644) for the treatment of various relapsed or refractory hematologic malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). While the trial also investigates CAR T-cells targeting CD30 for Hodgkin lymphoma and T-cell lymphoma, this specific intervention is focused on CD19-positive disease.

Other names

anti-CD19-CAR T-cellsanti-CD-19-CAR T-cellsanti-CD 19-CAR T-cellsCD19-targeted CAR T-cellsCD-19-targeted CAR T-cellsCD 19-targeted CAR T-cellsanti-CD19 chimeric antigen receptor T-cellsanti-CD-19 chimeric antigen receptor T-cellsanti-CD 19 chimeric antigen receptor T-cellsanti-CD19-CAR T-cells (Affiliated Hospital of Nantong University)